Arbutus Biopharma

ABUS

Börsenwert 840 Mio. $

#	Name	Position	Handelswert	Veränderung Aktien	Anteils- änderung
1	1 QVT Financial New York	99,3 Mio. $	–	–	–
2	2 RTW Investments New York	32,7 Mio. $	+241.484 $	+56.457	+1 %
3	3 Primecap Management Pasadena, California	24,7 Mio. $	+171.092 $	+40.000	+1 %
4	4 Ladenburg Thalmann Financial Services Miami, Florida	13,3 Mio. $	-15,1 Mio. $	-3.526.054	-67 %
5	5 D.E. Shaw & Co New York	10,9 Mio. $	+83.732 $	+19.576	+1 %
6	6 Bank of Montreal Toronto, Ontario, Canada	5,29 Mio. $	-86.936 $	-20.325	-2 %
7	7 Axa Paris, France	3,57 Mio. $	-881.120 $	-205.999	-26 %
8	8 Morgan Stanley New York	2,61 Mio. $	+403.576 $	+94.353	+29 %
9	KPF 9 K2 Principal Fund Toronto, Ontario, Canada	1,55 Mio. $	-538.251 $	-125.839	-33 %
10	10 Point72 Asset Management Stamford, Connecticut	1,39 Mio. $	+960.917 $	+224.655	Neu
11	BBA 11 Baker Bros. Advisors New York	1,12 Mio. $	–	–	–
12	12 Credit Suisse Zurich, Switzerland	1,09 Mio. $	+389 $	+91	+0,1 %
13	13 Renaissance Technologies New York	996.000 $	-212.278 $	-49.629	-24 %
14	14 Deutsche Bank Frankfurt Am Main Ge, Germany	811.000 $	-217.877 $	-50.938	-28 %
15	15 Victory Capital Management San Antonio, Texas	801.000 $	-15.184 $	-3.550	-3 %
16	16 Oxford Asset Management Oxford, United Kingdom	778.000 $	+175.211 $	+40.963	+49 %
17	17 Schonfeld Strategic Advisors New York	775.000 $	+534.663 $	+125.000	Neu
18	18 Hudson Bay Capital Management Stamford, Connecticut	732.000 $	-757.082 $	-177.000	-60 %
19	19 Invesco Atlanta, Georgia	700.000 $	+63.462 $	+14.837	+15 %
20	TI 20 Telemetry Investments New York	682.000 $	-463.659 $	-108.400	-50 %
21	21 Vanguard Group Malvern, Pennsylvania	488.000 $	+5.223 $	+1.221	+2 %
22	22 Barclays London, United Kingdom	470.000 $	+12.580 $	+2.941	+4 %
23	23 UBS Group Zurich, Switzerland	326.000 $	+224.349 $	+52.451	+45.610 %
24	24 Mackenzie Financial Toronto Ontario, Ontario, Canada	247.000 $	–	–	–
25	25 Scotia Capital Toronto, Ontario, Canada	196.000 $	+43.415 $	+10.150	+47 %

Arbutus Biopharma ABUS Börsenwert 840 Mio. $

Arbutus Biopharma

ABUS

Börsenwert 840 Mio. $